EDWARD MARK SCOLNICK
Medical Practice in Wayland, MA
License number
Pennsylvania MD027859E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Wayland, MA 01778
Pennsylvania
Pennsylvania
Professional information
Compositions Of Modulators Of The Wnt/Beta-Catenin Pathway And Benzamide And/Or Hydroxamic Acid Derivatives To Treat Bipolar Disorder
US Patent:
2013003, Feb 14, 2013
Filed:
Dec 23, 2009
Appl. No.:
13/141747
Inventors:
Daniel Fass - Winchester MA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Assignee:
UNIVERSITY OF WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 31/167, A61K 31/4406, A61P 25/00, A61K 31/513, A61K 33/14, A61K 33/00, A61K 31/4045, A61K 31/194
US Classification:
424677, 514616, 514415, 514357, 514574, 514274, 424715
Abstract:
The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.